Clinical Trials

Phase 1 Not yet recruiting

Biliary Tract Neoplasms

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Phase 1/2 Not yet recruiting

Biliary Tract Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Phase NA Not yet recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07169916 2025-09-12

YJ-BTC

210 enrolled

Biliary Tract Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07160283 2025-09-08

The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer

96 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT07129018 2025-08-19

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

63 enrolled

Biliary Tract Neoplasms

NCT07109167 2025-08-07

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Biliary Tract Neoplasms

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07003815 2025-06-04

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

62 enrolled

Biliary Tract Neoplasms

NCT06993025 2025-05-28

Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

Phase 3 Not yet recruiting

Biliary Tract Neoplasms

NCT06622057 2025-04-30

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

195 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

74 enrolled

Phase 4 Not yet recruiting

Biliary Tract Neoplasms

NCT06818773 2025-02-10

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

35 enrolled

Biliary Tract Neoplasms

NCT06654947 2024-12-16

A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

23 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

206 enrolled

Biliary Tract Neoplasms

NCT04910386 2024-08-14

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

126 enrolled

Biliary Tract Neoplasms

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

80 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06502080 2024-07-17

RADITOP

128 enrolled

Biliary Tract Neoplasms

NCT06389500 2024-04-29

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Phase NA Not yet recruiting

Biliary Tract Neoplasms

NCT06375928 2024-04-19

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)

44 enrolled

Phase NA Not yet recruiting

Biliary Tract Neoplasms

NCT06171321 2023-12-14

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma

94 enrolled

Biliary Tract Neoplasms

NCT06037655 2023-09-14

Modified